{
  "id": 20960885,
  "title": "Pfizer's Launched and Acquired Drugs Grew 32% in Q3 — and 3 Other Reasons to Buy the Stock Before 2027",
  "url": "https://urgent.news/2026/11/20/pfizers-launched-and-acquired-drugs-grew-32-in-q3-and-3-other-reasons",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-20T22:15:02.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/11/20/pfizers-launched-and-acquired-drugs-grew-32-in-q3-and-3-other-reasons-to-buy-the-stock-before-2027/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Pfizer (PFE -0.51%) is facing challenges due to an upcoming patent cliff, with key drugs such as Eliquis expiring in 2028 and Vyndamax in 2031. However, the company has reported a significant 32% revenue growth in the third quarter of 2026 from its launched and acquired drugs, indicating progress in addressing the patent cliff issue. Despite these achievements, investors have largely remained negative on Pfizer's stock, reflected in a high dividend yield of 6.1%, which is much higher than the S&P 500's 1.1% and the average pharma stock's 1.3%.\n\nOne of the reasons to consider buying Pfizer's stock is its robust balance sheet. As of the third quarter of 2026, Pfizer had $1.8 billion in cash and $12.4 billion in short-term investments, demonstrating a strong financial position that could help it navigate the patent expiration period. This financial strength, along with its stock's attractive valuation, makes it an intriguing investment opportunity. Furthermore, Pfizer's commitment to maintaining and growing its dividend is evident in its strong cash dividend payout ratio of roughly 85%, despite earnings not fully covering the dividend. The company's leadership in the pharmaceutical industry, coupled with its focus on innovation and financial stability, makes it a compelling choice for investors looking for a reliable dividend stock.",
  "summary": "Pfizer remains deeply unloved on Wall Street, but it is slowly turning a corner.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "2 Reasons to Buy SpaceX (SPCX) Stock -- and 1 Reason to Wait",
        "url": "https://urgent.news/2026/11/19/2-reasons-to-buy-spacex-spcx-stock-and-1-reason-to-wait-20813595",
        "published": "2026-11-19T22:04:01.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}